Allergologia et immunopathologia

Sociedad Española de Inmunología Clínica, Alergología y Asma Pediátrica

www.elsevier.es/ai

ORIGINAL ARTICLE

Effects of icariin on asthma mouse model are associated with regulation of prostaglandin D2 level

CrossMark

J. Qiao, S. Sun, L. Yuan, J. Wang*

Department of Respiratory Medicine, The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract
Background: We aimed to observe the effect of icariin on an asthma mouse model and explore the potential underlying mechanisms.
Methods: The asthma mouse model was established by ovalbumin (OVA) sensitisation and respiratory syncytial virus (RSV) infection and then treated with icariin. Airway resistance was assessed by whole body plethysmograph. In addition, pathological slides were stained with haematoxylin–eosin, and the peribronchial inflammation was observed microscopically. The concentration of prostaglandin D2 (PGD2) in serum and bronchoalveolar lavage fluid (BALF) was detected by enzyme-linked immuno sorbent assay (ELISA). The relative level of prostaglandin D2 receptor 2 (CRTH2) mRNA was assessed by real-time quantitative PCR.
Results: Compared with the icariin-untreated group, there was a significant reduction of Penh in the treated group. Total leucocyte amount and all sorts of leukocytes were lower in the treated group than in the untreated group. HE staining results revealed that a large number of inflammatory cells infiltrated into the peribronchial tissues of untreated group, and the degree of airway inflammation decreased significantly in the treated group. PGD2 in serum and BALF, as well as CRTH2 mRNA level in lung tissues were lower in the treated group than in the untreated group.
Conclusion: Icariin is a promising therapeutic strategy for asthma, and PGD2 might be a new target for asthma therapy in OVA-induced and RSV-infected asthma model.
© 2017 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

* Corresponding author.
  E-mail address: qjou@163.com (J. Wang).

Introduction

Bronchial asthma is a chronic inflammatory disease of the airway, involving many cellular elements and cells, such as eosinophils, mast cells, T lymphocytes, neutrophils and airway epithelial cells.[1] The prevalence and mortality of asthma is in an upward trend, which makes this chronic disease one of the main serious problems to public health.[2] The main treatments for asthma are non-specific anti-inflammatory drugs and bronchodilators.[3] In recent years, developing therapy methods are emerging, including anti-IgE therapy, leukotriene modifying drugs, immunotherapy and bronchial thermoplasty.[4] However, these methods should be improved with respect to cost and/or side effects.

Icariin is one of the main ingredients of *Herba epimedii*, with the ability of relieving asthma and cough, anti-allergy activity and enhancing humoral immunity and cellular immunity.[5] Modern pharmacological studies indicate that icariin was also associated with immune regulation, antibacterial and anti-asthmatic effects.[6] It could significantly boost immunity of the respiratory tract, improve asthmatic symptoms, reduce the production of inflammatory mediators, improve the endogenous anti-inflammatory ability of the body, shorten the sustaining duration, and reduce the frequency of asthma. Moreover, icariin is confirmed to be effective in the therapy of respiratory syncytial virus (RSV)-induced asthma.[7,8] However, the specific mechanism remains unclear.

In order to verify the therapeutic effect of icariin on asthma and to explore the underlying mechanisms, a mouse asthma model was constructed and treated with icariin in this study. The airway resistance and the pathological feature of lung tissue were observed. Simultaneously, the concentration of prostaglandin D2 (PGD2) and relative level of prostaglandin D2 receptor 2 (CRTH2) mRNA were assessed.

Materials and methods

Animals

A total of 30 four-week-old female specific-pathogen-free BALB/c mice, weighing 16–19 g, were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. These animals received food and water ad libitum in a reversed 12:12-h light/dark cycle. Two weeks later, these mice were randomly divided into three groups, ovalbumin (OVA)/RSV-Y group, OVA/RSV-N group, and the control group (n = 10 in each group). The asthma model was constructed in mice of the OVA/RSV-Y group and OVA/RSV-N group. Normal mice in the control group served as blank control. All animal care and experimentation were performed in compliance with the Regulations for Administration of Affairs Concerning Experimental Animals (China, 2010), and approved by the Animal Ethics Committee of Shanghai Jiao Tong University.

Model construction and intervention

The asthma model was constructed in both the OVA/RSV-Y group and the OVA/RSV-N group with OVA sensitisation. In detail, mice were firstly anaesthetised by methoxyflurane inhalation, and then immunised on days 0 and 7 by intraperitoneal injection with 20 μg OVA (GradeV; Sigma–Aldrich, St. Louis, USA) emulsified in 200 μl of PBS buffer containing 2.25 mg aluminium hydroxide adjuvant. From days 14 to 16, 25 μl RSV (Shanghai Genechem Co., Ltd., China) with a titre of 10^7 pfu was dropped nasally to each mouse. RSV titre in lung tissues were examined on day 17. To verify whether the asthma model was successfully constructed, three mice from each of these two groups were sacrificed and pulmonary function was tested. From days 22 to 24 and days 29 to 31, each mouse was challenged by nasally dropping 25 μl RSV at the titre of 10^7 pfu. Then, 2.5 mg icariin (Kailai Biotech Co., Ltd., China) in 200 μl normal saline was intraperitoneally injected to mice in the OVA/RSV-Y group once a week for two consecutive weeks. An equal volume of sterile water was administered to mice in the control group through the whole procedure.

RSV titres in lung tissue

RSV titres were detected on day 17 as follows. Lungs of three mice in both the OVA/RSV-Y group and the OVA/RSV-N group were aseptically removed. Approximately 0.1 g lung tissue was homogenised in 1 ml Dulbecco's PBS (GIBCO), and then added to confluent monolayers of Vero cells for RSV titre detection. Thereafter, the monolayer was cultured at 37 °C for three days, and RSV plaques were calculated after immunostaining with monoclonal antibodies against the G and F glycoproteins as described in previous studies.[9,10]

Airway reactivity measurement

On days 21 and 35, airway responsiveness to methacholine (Mch, Sigma–Aldrich, St. Louis, USA) was assessed by whole-body plethysmography (WBP, Buxco Electronics Inc., Troy, NY, USA) in a dose-dependent manner (3.125, 6.25, 12.5, 25, 50 mg/ml of methacholine in PBS). Airway reactivity, as the indicator for respiratory function, was determined by interpolation of the dose–response curve for enhanced pause (Penh).

Cell identification and PGD2 measurement of bronchoalveolar lavage fluid

After airway reactivity measurement, the mice's trachea was cannulated by 22G venous indwelling needle in a supine position. The right lung was ligated at the right main branch of the trachea using surgical forceps, and the left lung was lavaged by tracheal cannula with 0.5 ml phosphate-buffered saline (PBS, Sigma–Aldrich, St. Louis, USA) for three times. The retrieved bronchoalveolar lavage fluid (BLAF) was pooled and centrifuged at 2000 r/min for 10 min at 4 °C. The supernatant was collected and stored at −80 °C for PGD2 level detection and cell identification. Moreover, blood was collected by enucleation of eyeball, and serum was separated in a refrigerated centrifuge at 4 °C and stored at −80 °C. In this study, PGD2 level in serum and BLAF was detected using the Enzyme-linked Immunosorbent Assay (ELISA) kit (Uscn Life Science Inc., China), and the leucocyte were counted and classified into neutrophil (Neu), lymphocyte (Lym), monocyte (Mon), eosinophil (Eos)

and basophil (Bas) by BC-2800 Vet blood analyser (Mindray, China).

Immunohistochemical analysis for lung tissue

The right lobe of the lung was inflated and fixed immediately in 10% neutral buffered formalin for 24 h, followed by dehydration, transparency and paraffin embedding. The blocks were cut into 5 μm segments. Airway inflammation was assessed by haematoxylin and eosin staining. Histological sections were blindly observed using a light microscope.

Real-time quantitative PCR for CRTH2 level

Based on the manufacturer's instructions, total RNA was extracted and purified from lung tissue with Trizol reagent (Invitrogen). The concentration and purity were measured by the spectrophotometric absorbance at 260 and 280 nm. Reverse transcription process of RNA to cDNA was undertaken by adding 2 μg RNA to a solution with an oligo-dT primer and reverse transcriptase (Promega Co., USA). Quantitative real-time PCR was performed in a total volume of 20 μl containing 1 μl template DNA, 1 μl sense and antisense primers, 7 μl H_2O and 10 μl SYBR Green Master Mix (ABI, USA) using the STRATAGENE MX3000 system (Agilent, USA). The primers were designed as follows: β-actin: sense 5′-CTG TCCCTG TAT GCC TCTG-3′, antisense 5′-TGT CACGCACGATTT CC-3′; CRTH2: sense 5′-TAT CCG ACT TGT TAG CCG CC-3′, antisense 5′-TTG CAG AAGGTAGTG CCC AG-3′. After incubation at 95 °C for 10 min, the mixtures were subjected to 40 cycles of 30 s at 95 °C, 30 s at 57 °C and 45 s at 75 °C. The fold change of each gene was calculated using the $\triangle\triangle Ct$ method with β-actin gene as an internal control. The final data were presented as fold change compared to the gene expression of mice in the normal control group.

Statistical analysis

Statistical analysis was performed using SPSS 19.0 software (version 19.0; SPSS Inc., Chicago, IL, USA). The experimental data were represented as mean ± standard deviation (SD). Student's t-test was used for the intergroup comparison. $P < 0.05$ was considered to be statistically significant.

Results

General observation

After being sensitised by OVA and infected by RSV, the mice in the OVA/RSV-Y group and the OVA/RSV-N group showed asthma symptoms including piloerection, dysphoria, scratching head and back, polypnea, nodding breathing and abdominal muscle twitch compared with those in the control group. After icariin treatment, symptoms of dysphoria and polypnea were alleviated in the OVA/RSV-Y group compared with those in the OVA/RSV-N group.

Lung functional test

In the three groups, the Penh of mice was increased with the methacholine concentration. Compared with the control


Figure 1 The relationship between Penh and the methacholine concentration in the OVA/RSV-Y, OVA/RSV-N, and control groups. *Note*: ** represents $P < 0.01$ when the OVA/RSV-Y group was compared with the OVA/RSV-N group; $\triangle$ represents $P < 0.01$ when the OVA/RSV-N group was compared with the control group.

group, Penh of mice in the OVA/RSV-Y and OVA/RSV-N groups was significantly higher ($P < 0.05$). In addition, the Penh in the OVA/RSV-Y group was significantly higher than that in the OVA/RSV-N group (Fig. 1). These results indicated that icariin could decrease the Penh in mice asthma model.

Effects of icariin on PGD2 level in serum and BALF

As shown in Fig. 2, in both serum and BALF, the PGD2 level was higher in the OVA/RSV-N group than that in control group ($P < 0.01$), while the PGD2 level in the OVA/RSV-Y group was significantly lower than that in the OVA/RSV-N group ($P < 0.01$). The results showed that the PGD2 level increased in the mouse asthma model, and decreased by icariin treatment.

Cell classification and count in BALF

As shown in Fig. 3, the amount of each type of leucocytes significantly increased in BALF of mice in the OVA/RSV-Y and OVA/RSV-N group, while icariin could significantly decrease the leucocyte amount. However, the amount was still significantly higher in the OVA/RSV-Y group than that in the control group.

Immunohistochemical analysis for lung tissue

Compared with mice in the control group, the tracheal wall in the OVA/RSV-N group was obviously thickened, and the lumen of the airway was narrowed. In addition, massive inflammatory cells including neutrophils, lymphocytes and monocyte infiltrated the airway. However, few eosinophils were observed. After treatment with icariin, there was a remission in the thickened walls and narrowed lumens of the

Figure 2   PGD2 level in BALF and serum. *Note*: **showed *P* < 0.01 when the OVA/RSV-Y group was compared with the OVA/RSV-N group; △ showed *P* < 0.01 when the OVA/RSV-N group was compared with the control group.


Figure 3   Total cells in BALF. *Note*: **showed *P* < 0.01 when the OVA/RSV-Y and the OVA/RSV-N group were compared with the control group; △ showed *P* < 0.01 when the OVA/RSV-N group was compared with the OVA/RSV-Y group.

airway, and inflammatory cellular infiltration was alleviated (Fig. 4).

Effects of icariin on CRTH2 mRNA level in lung tissue

As shown in Fig. 5, real-time PCR revealed significantly higher level of CRTH2 mRNA in the OVA/RSV group compared with that in the control group (*P* < 0.01). Besides, icariin treatment significantly reduced the CRTH2 mRNA level in the OVA/RSV-Y group when compared with that in the OVA/RSV-N group.

Discussion

In this study, an asthma model sensitised by OVA and infected by RSV was successfully established. After treatment with icariin, lung function of asthmatic mice was significantly improved, and the thickened walls and narrow lumens of the airway, as well as the infiltration of inflammatory cells in lung tissue were relieved to some extent. Meanwhile, all sorts of leukocytes in BALF, PGD2 level in both serum and BALF, and the CRTH2 mRNA level in lung tissue were obviously decreased following icariin treatment.


Figure 4   Pathological changes of lung tissues observed by HE staining (light microscopy, ×200). (A) Control group; (B) OVA/RSV-N group; (C) OVA/RSV-YYH group.

Figure 5 Relative CRTH2 Mrna in lung tissue. *Note*: **showed *P* < 0.01 when the OVA/RSV-Y group was compared with the OVA/RSV-N group; △ showed *P* < 0.01 when the OVA/RSV-N group was compared with the control group.

A previous study has confirmed that OVA could induce a significant increase in airway resistance and also weaken the lung dynamic compliance.[11] Respiratory viral infection plays an important role in the acute attack and exacerbation of bronchial asthma.[12] For people with susceptibility factors for asthma, exposure to RSV may directly contribute to asthma or at least invoke pathophysiological changes in lung tissues.[13] In turn, activation of immune responses during RSV infection can increase the susceptibility to asthma.[14,15] Additionally, there was a significant leucocyte influx into BALF in the OVA-induced asthma model.[16] Previous studies confirmed that icariin could also reduce inflammatory cytokine infiltration and recover the ability of glucocorticoid responsiveness.[17] Moreover, icariin has been confirmed to possess the anti-inflammatory activities and weaken the inflammation in an asthma model.[18,19] In this present study, icariin was found to prominently improve asthmatic symptoms and lung function, which was in line with the previous studies.

In the complex mechanisms of asthma, various factors have been revealed to lay a foundation for asthma treatment. For instance, a previous study demonstrated that the effect of icariin on the attenuation of airway hyperresponsiveness and chronic airway inflammatory changes in OVA-induced murine asthma model may be associated with regulation of Th17/Treg responses.[20] PGD2, mostly derived from mast-cell activation, is an important inflammatory mediator. It could not only evoke intense contraction of bronchia, but also increase the capillary permeability.[21] PGD2 is considered to be responsible for bronchoconstriction, eosinophils infiltration and mucosa secretion in allergic asthma. Moreover, increased PGD2 could also promote chemotaxis of eosinophils and makes eosinophils infiltrate into the airway resulting in eosinophils infiltration in the pathology of asthma.[22] In addition, it regulated fibroblast formation and transformation, and also participated in the airway remodelling in the same time.[23] The changes of PGD2 lead to the accumulation of cytokines and chemotaxin, lymphocytes and eosinophils, and further induce a series of

anaphylaxis. Besides, the level of PGD2 and its metabolites in BALF of asthmatic patients has been found to be increased, especially after challenged by allergens such as CRTH2.[24–27] CRTH2 is one of PGD2 receptors, and PGD2 could promote eosinophils responding and matrix contraction via acting with CRTH2, and further regulate tissue repair.[28,29] Endogenous PGD2 produced by various causes may trigger an inflammatory reaction through the enhanced expression of CRTH2 in eosinophils.[30] In the present study, PGD2 in serum and BALF and the CRTH2 mRNA level in lung tissue were found to be significantly increased in asthmatic mice. After treatment with icariin, the relative levels of PGD2 and CRTH2 were all decreased, which indicates that the therapeutic effects of icariin on asthma may be associated with the regulation of PGD2.

In conclusion, icariin treatment may be a promising therapeutic strategy for asthma, and PGD2 may be a new target for asthma therapy in OVA-induced and RSV-infected asthma model.

Conflict of interest

None.

Ethical disclosures

Confidentiality of data. The authors declare that no patient data appears in this article.

Right to privacy and informed consent. The authors declare that no patient data appears in this article.

Protection of human subjects and animals in research. The authors declare that no experiments were performed on humans or animals for this investigation.

References

1. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8:183–92.
2. Akinbami OJ. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010; 2012.
3. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155:291–9.
4. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356:1327–37.
5. Bao Y, Jing C, Shi W. Effects of Chinese herbal recipes on immunity in immunosuppressive mice. Afr J Tradit Complement Altern Med. 2012;9:548–52.
6. Zhou J, Wu J, Chen X, Fortenbery N, Eksioglu E, Kodumudi KN, et al. Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int Immunopharmacol. 2011;11:890–8.
7. Nurahmat M, Chen M, Luo Q, Ling Y, Dong J, Huang C. Rapid characterization and determination of multiple components in

Bu-Shen-Yi-Qi-Fang by high-performance liquid chromatography coupled to electrospray ionization and quadrupole time-of-flight mass spectrometry. J Sep Sci. 2014;37:3509–17.

8. Wang J, Wu J, Kong L, Nurahmat M, Chen M, Luo Q, et al. BuShenYiQi formula strengthens Th1 response and suppresses Th2–Th17 responses in RSV-induced asthma exacerbated mice. J Ethnopharmacol. 2014;154:131–47.

9. Tripp RA, Moore D, Jones L, Sullender W, Winter J, Anderson LJ. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol. 1999;73:7099–107.

10. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol. 2001;75:10730–7.

11. Wei Y, Liu B, Sun J, Lv Y, Luo Q, Liu F, et al. Regulation of Th17/Treg function contributes to the attenuation of chronic airway inflammation by icariin in ovalbumin-induced murine asthma model. Immunobiology. 2015;220:789–97.

12. Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007;119:1105–10.

13. Schaller M, Hogaboam CM, Lukacs N, Kunkel SL. Respiratory viral infections drive chemokine expression and exacerbate the asthmatic response. J Allergy Clin Immunol. 2006;118:295–302, quiz 3-4.

14. Mejias A, Ramilo O. Asthma and respiratory syncytial virus. Myth or reality? An Esp Pediatr. 2002;57:199–204.

15. Mohapatra SS, Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev. 2008;21:495–504.

16. Dong F, Wang C, Duan J, Zhang W, Xiang D, Li M. Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model. Evid Based Complement Alternat Med. 2014;2014:726740.

17. Li B, Duan X, Xu C, Wu J, Liu B, Du Y, et al. Icariin attenuates glucocorticoid insensitivity mediated by repeated psychosocial stress on an ovalbumin-induced murine model of asthma. Int Immunopharmacol. 2014;19:381–90.

18. Luo QL, Nurahmat M, Li MH, Sun J, Chen MX, Liu F, et al. Pharmacological investigation of a HPLC/MS standardized three herbal extracts containing formulae (Bu-Shen-Yi-Qi-Tang) on airway inflammation and hypothalamic–pituitary–adrenal axis activity in asthmatic mice. Phytomedicine. 2014;21:1439–50.

19. Xu CQ, Liu BJ, Wu JF, Xu YC, Duan XH, Cao YX, et al. Icariin attenuates LPS-induced acute inflammatory responses:

involvement of PI3K/Akt and NF-kappaB signaling pathway. Eur J Pharmacol. 2010;642:146–53.

20. Wei Y, Luo QL, Sun J, Chen MX, Liu F, Dong JC. Bu-Shen-Yi-Qi formulae suppress chronic airway inflammation and regulate Th17/Treg imbalance in the murine ovalbumin asthma model. J Ethnopharmacol. 2015;164:368–77.

21. Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93–104.

22. Uller L, Mathiesen JM, Alenmyr L, Korsgren M, Ulven T, Högberg T, et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007;8:16.

23. Kohyama T, Wyatt TA, Liu X, Wen F-Q, Kobayashi T, Fang Q, et al. PGD2 modulates fibroblast-mediated native collagen gel contraction. Am J Respir Cell Mol Biol. 2002;27:375–81.

24. Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol. 2013;131:1504–12.

25. Liu H, Zheng M, Qiao J, Dang Y, Zhang P, Jin X. Role of prostaglandin D2/CRTH2 pathway on asthma exacerbation induced by *Aspergillus fumigatus*. Immunology. 2014;142:78–88.

26. Garcia-Solaesa V, Sanz-Lozano C, Padron-Morales J, Hernandez-Hernandez L, Garcia-Sanchez A, Rivera-Reigada ML, et al. The prostaglandin D2 receptor (PTGDR) gene in asthma and allergic diseases. Allergol Immunopathol (Madr). 2014;42:64–8.

27. Singh D, Cadden P, Hunter M, Pearce Collins L, Perkins M, Pettipher R, et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J. 2013;41:46–52.

28. Lordan JL, Bucchieri F, Richter A, Konstantinidis A, Holloway JW, Thornber M, et al. Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells. J Immunol. 2002;169:407–14.

29. Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med. 2001;164:1487–94.

30. Gervais FG, Cruz RP, Chateauneuf A, Gale S, Sawyer N, Nantel F, et al. Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD 2 receptors CRTH2 and DP. J Allergy Clin Immunol. 2001;108:982–8.